Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Cert. of designation
Quarterly results
Appointed COO
Appointed director
Perspective Therapeutics, Inc. (ISR) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
08/22/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/22/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/18/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Quarterly results
08/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
07/25/2023 8-K Quarterly results
07/14/2023 8-K Quarterly results
07/13/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/13/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Appointed a new director
Docs: "Press Release"
05/01/2023 10-KT Form 10-KT - Transition reports [Rule 13a-10 or 15d-10]:
04/21/2023 8-K/A Quarterly results
03/15/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation"
03/13/2023 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Separation Agreement between Perspective Therapeutics, Inc., Isoray Medical, Inc., and William Cavanagh III, effective March 10, 2023"
03/13/2023 8-K Other Events  Interactive Data
02/10/2023 8-K Quarterly results
02/06/2023 8-K Appointed a new director
Docs: "Form of Registration Rights and Lock-Up Agreement",
"Separation Agreement between Isoray Inc. and Lori A. Woods",
"Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine"
01/30/2023 8-K Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits &...
Docs: "Isoray Announces Results of Fiscal 2023 Annual Meeting of Stockholders"
01/12/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
01/12/2023 8-K Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits &...
Docs: "Isoray Announces Adjournment of Annual Meeting of Stockholders to January 27, 2023 RICHLAND, WASHINGTON – January 12, 2023 – Isoray, Inc. , a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the January 12th, 2023, adjourned Annual Meeting of Stockholders is being adjourned until January 27th, 2023, to provide stockholders who have not yet voted with additional time to vote on Proposal 1, approval of an amendment to the Company’s Certificate of Incorporation to increase the total number of authorized shares of Common Stock. This vote, which requires approval by a majority of the outstanding shares, is required to proceed with the proposed merger with Viewpoint Molecular Targeting, Inc. The Board of..."
12/14/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
12/14/2022 8-K Quarterly results
12/06/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
11/29/2022 8-K Quarterly results
11/16/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
11/07/2022 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
10/25/2022 PREM14A Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
10/24/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/24/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy